reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
Hyloris XTRAZA license and supply agreement with Huons in South Korea
Hyloris announced that an exclusive license and supply agreement has been signed with Huons for XTRAZA in South Korea. Under the terms, Hyloris will exclusively supply XTRAZA to Huons though further financial terms were not disclosed. This deal follows previously announced agreements in selected APAC regions and Canada with AFT, and in the UK with Colonis Pharma. A phase 3 trial for XTRAZA is ongoing in the US and EU, with data expected by YE25, and we note that a deal for XTRAZA in the larger U...
- ING Helpdesk
- Jacob Mekhael
- Jacob Mekhael
Onward Medical Receives FDA green light to begin pivotal ARC-IM blood ...
Onward announced that it has received FDA investigational device exemption (IDE) approval to initiate the pivotal Empower BP study with the ARC-IM implantable system to address blood pressure instability after spinal cord injury (SCI). First patient enrolment in the pivotal study is anticipated before YE25, and we look forward to the detailed interim analysis from an earlier feasibility study due later this year, as well as additional details on the pivotal study design and timelines. We reitera...
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pi...
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI).Managing blood pressure instability is a major unmet need after SCI, with a signific...
- Pierre FerraguÊ
TSLA TESLA INC
NVDA NVIDIA CORPORATION
COHR COHERENT INC.
AMAT APPLIED MATERIALS INC.
2330 TSMC
00992 LENOVO GROUP LIMITED
3661 ALCHIP TECHNOLOGIES INC.
00700 TENCENT HOLDINGS LTD.
CSCO ASML HOLDING N.V.
ASML CISCO SYSTEMS INC.
40978Z ASML HOLDING NV
2357 TT HUAWEI TECHNOLOGIES CO
ASUSTEK COMPUTER
- Pierre FerraguÊ
- Marc Hesselink
- CFA
- Thymen Rundberg
ASML/Slower 2026, long-term intact/BUY
Despite a slower growth outlook for 2026 we remain positive on the ASML investment case. We believe that the long-term outlook for semiconductor capex remains strong. On top of that, we expect continued increases in litho intensity resulting in above-industry growth. The current valuation close to previous lows, the risk-reward is attractive in our view. We reiterate our BUY rating but slightly lower our target price from €825 to €800 per share.
ONWARD Medical gibt Ernennung von Lucas Buchanan als Vorstandsmitglied...
ONWARD Medical gibt Ernennung von Lucas Buchanan als Vorstandsmitglied bekannt Buchanan ist ehemaliger CFO und COO von Silk Road Medical, wo er erfolgreich ein Medizintechnikunternehmen in der Wachstumsphase skalierte, das schließlich von Boston Scientific übernommen wurde.Buchanan, früher Risikokapitalgeber bei der Vertical Group, ist außerdem aktiver Investor, Berater und Vorstandsmitglied mehrerer innovativer Medizintechnikunternehmen und Gesundheitsinvestitionsfonds. EINDHOVEN, Niederlande, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD und US OTCQX: ONWRY), da...
ONWARD Medical annonce la nomination de Lucas Buchanan à son conseil d...
ONWARD Medical annonce la nomination de Lucas Buchanan à son conseil d’administration M. Buchanan est l’ancien directeur financier et directeur des opérations de Silk Road Medical, où il a développé avec succès une entreprise de dispositifs médicaux en phase de croissance, aboutissant à son acquisition par Boston Scientific.Ancien investisseur en capital-risque chez Vertical Group, M. Buchanan est également un investisseur actif, conseiller et membre du conseil d’administration de plusieurs entreprises innovantes dans le domaine des dispositifs médicaux et de fonds d’investissement dans le ...
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Boar...
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific. Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds. EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurote...
- Pierre FerraguÊ
- Pierre FerraguÊ
- Stijn Demeester
- Pierre FerraguÊ
- Pierre FerraguÊ
ASML: best positioned for 2026 in the Semicap pack. Upgrade to Buy, €7...
Consensus expects ASML to grow revenues 2% next year, compared to 6-12% for its peers. That is conservative. If anything, we see room for ASML to outperform, driven by high leading-edge exposure. Beyond 2026, we also expect ASML to grow in the upper end of its peer group. Normal order intake in 3Q would allow management to ease concerns around 2026 growth, and with the stock trading on 25x forward earnings we see limited risk of further de-rating. We hence upgrade the stock to Buy, €790 Target...
- Stefano Toffano
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
GIVN GIVAUDAN SA
SRT3 SARTORIUS AG PREF
CPG COMPASS GROUP PLC
HOT HOCHTIEF AG
ISP INTESA SANPAOLO S.P.A.
RY4C RYANAIR HOLDINGS PLC
UCG UNICREDIT S.P.A.
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
AKZA AKZO NOBEL N.V.
STLA STELLANTIS N.V.
VWS VESTAS WIND SYSTEMS
- Stefano Toffano
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
GIVN GIVAUDAN SA
SRT3 SARTORIUS AG PREF
CPG COMPASS GROUP PLC
HOT HOCHTIEF AG
ISP INTESA SANPAOLO S.P.A.
RY4C RYANAIR HOLDINGS PLC
UCG UNICREDIT S.P.A.
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
AKZA AKZO NOBEL N.V.
STLA STELLANTIS N.V.
VWS VESTAS WIND SYSTEMS
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.